Adolescent‐ and adult‐onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020
Orlane Magnier,Isabelle Schiff,Justine Cristante,Olivier Chabre,Melanie Veloso,Jean‐Luc Bosson,Anne‐Sophie Defachelles,Camille Cordero,Christine Do Cao,Estelle Thebaud,Delphine Drui,Pablo Berlanga,Benoit Dumont,Philippe Chastagner,Julie Tandonnet,Marion Gambart,Sarah Jannier,Claire Pluchart,Leslie Andry,Véronique Laithier,Sébastien Klein,Liana Carausu,Tasmine Akbaraly,Jamie Probert,Raphaelle Habert‐Dantigny,Dominique Plantaz
DOI: https://doi.org/10.1002/pbc.31074
2024-05-24
Pediatric Blood & Cancer
Abstract:Background Adult‐ and adolescent‐onset neuroblastomas are rare, with no established therapy. In addition, rare pheochromocytomas may harbor neuroblastic components. This study was designed to collect epidemiological, diagnostic and therapeutic data in order to better define the characteristics of malignant peripheral neuroblastic tumors (MPNT) and composite pheochromocytomas (CP) with MPNT. Procedure Fifty‐nine adults and adolescents (aged over 15 years) diagnosed with a peripheral or composite neuroblastic tumor, who were treated in one of 17 institutions between 2000 and 2020, were retrospectively studied. Results Eighteen patients with neuroblastoma (NB) or ganglioneuroblastoma (GNB) had locoregional disease, and 28 patients had metastatic stage 4 NB. Among the 13 patients with CP, 12 had locoregional disease. Fifty‐eight percent of the population were adolescents and young adults under 24 years of age. The probability of 5‐year event‐free survival (EFS) was 40% (confidence interval: 27%–53%). Conclusions Outcomes were better for patients with localized tumor than for patients with metastases. For patients with localized tumor, in terms of survival, surgical treatment was the best therapeutic option. Multimodal treatment with chemotherapy, surgery, radiotherapy, and immunotherapy‐based maintenance allowed long‐term survival for some patients. Adolescent‐ and adult‐onset neuroblastoma appeared to have specific characteristics associated with poorer outcomes compared to pediatric neuroblastoma. Nevertheless, complete disease control improved survival. The presence of a neuroblastic component in pheochromocytoma should be considered when making therapeutic management decisions. The development of specific tools/resources (Tumor Referral Board, Registry, biology, and trials with new agents or strategies) may help to improve outcomes for patients.
oncology,pediatrics,hematology